Asif Ali - 27 Jan 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role: Chief Financial Officer
Signature: /s/ Matthew Gosling, Attorney-in-Fact for Asif Ali
Issuer symbol: PTGX
Transactions as of: 27 Jan 2026
Net transactions value: -$3,387,957
Form type: 4
Filing time: 27 Jan 2026, 21:20:42 UTC
Previous filing: 21 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ali Asif	Chief Financial Officer	C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK	/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali	27 Jan 2026	0001921163

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTGX	Common Stock	Options Exercise	$307,040	+16,000	+20%	$19.19	94,523	27 Jan 2026	Direct	F1
transaction	PTGX	Common Stock	Options Exercise	$146,040	+12,000	+13%	$12.17	106,523	27 Jan 2026	Direct
transaction	PTGX	Common Stock	Sale	$2,327,640	-28,000	-26%	$83.13	78,523	27 Jan 2026	Direct	F2
transaction	PTGX	Common Stock	Sale	$1,513,397	-18,203	-23%	$83.14	60,320	27 Jan 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTGX	Stock Option (right to buy)	Options Exercise	$0	-16,000	-24%	$0.000000	50,800	27 Jan 2026	Common Stock	16,000	$19.19	Direct	F4
transaction	PTGX	Stock Option (right to buy)	Options Exercise	$0	-12,000	-39%	$0.000000	18,547	27 Jan 2026	Common Stock	12,000	$12.17	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes an aggregate of 446 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2025.
F2	The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3	The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4	The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.
F5	The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.